Introduction
The ability of Filgrastim to ameliorate neutropenia postchemotherapy has been well documented [1] [2] [3] [4] [5] . Despite the volume of research using hematopoietic growth factors and their general availability in clinical practice, little is known about the optimum schedule for administration of these agents. Scheduling of these factors may have important implications for improving hematologic recovery post-chemotherapy as well as developing the most cost-effective strategy for the implementation of colony-stimulating factors in clinical practice.
In the initial phase 3 trial of patients with small-cell lung cancer (SCLQ receiving cyclophosphamide, doxonibicin, and etoposide (CAE) chemotherapy, Filgrastim was initiated 24 hours after the completion of the threeday chemotherapy regimen [4] . On this schedule, a 50% reduction in the overall duration of neutropenia occurred with a similar reduction in the incidence of febrile neutropenia. For patients receiving Filgrastim, the neutrophil count increased within 24 hours after the initiation of therapy. This group also experienced an earlier neutrophil nadir compared with the placebo group. The earlier neutrophil nadir may relate to the effect of Filgrastim on differentiation of the post-mitotic pool [6] . This may be distinct from the effect of Filgrastim on cell amplification and post-nadir neutrophil recovery.
The current study was performed to determine if altering the schedule of Filgrastim administration after chemotherapy would have further beneficial effects on hematologic recovery. Patients with extensive SCLC who met eligibility criteria similar to these of the previous phase 3 trial, were randomized to receive Filgrastim beginning on day 4, day 6, or day 8 of each cycle of chemotherapy. This schedule corresponded to one, three, or five days post-chemotherapy. The findings of this study suggest that this relatively minor alteration in schedule had a substantial effect on hematologic recovery.
Patients and methods
This phase 2, multicenter trial involved five investigators and at five centers. Forty-six patients were randomized between November 1990 and December 1991, but one patient did not receive treatment. This report summarizes the findings for the 45 evaluable patients.
Patients were eligible for enrollment if they had newly diagnosed, histologically or cytologically confirmed extensive stage SCLC. A Karnofsky performance status of 560%, a life expectancy of six A physical examination was conducted before each cycle of chemotherapy. A serum chemistry panel was done on day 1 of each cycle. During all cycles of therapy, patients were monitored for any adverse events and concomitant medications, as well as clinical response to treatment.
Study material
The Filgrastim (r-metHuG-CSF) used in this study was produced by Amgen Inc., Thousand Oaks, CA, by recombinant gene techniques using the E. coli system. Cyclophosphamide, doxorubicin, and etoposide (CAE), which are approved oncologic agents, were obtained from commercial sources. months, and a left ventricular ejection fraction (LVEF) >45% were also required. In addition, patients were to be 18 years of age and had to meet standard criteria for renal, hepatic, and hematologic status.
Patients were ineligible for enrollment if they had received prior chemotherapy or radiotherapy of any type, or if they had undergone major surgery within two weeks before randomization. Informed consent was obtained from all patients according to the guidelines of the Food and Drug Administration and the individual institutional review boards.
Statistical analysis
Forty-six patients were randomized in this three-arm, open-label, parallel-group trial. Descriptive statistics by arm and cycle are provided for the ANC nadir, incidence of fever with neutropenia (temperature >38.2°C, and ANC <0.5 x 10 9 /l), duration of ANC <0.5 x lO'/l), incidence of grade IV thrombocytopenia, median platelet nadir, incidence of platelet transfusions, number of units of platelets transfused, platelet count, incidence of red blood cell transfusions, and number of units of red blood cells transfused. These statistics were calculated for all patients, and then separately for those patients completing the study and for those patients who discontinued before the end of the sixth cycle. Due to the small sample sizes, no formal hypothesis testing was performed.
Treatment procedure
Patients were screened and subsequently randomized to one of three Filgrastim schedules, to be given in conjunction with CAE chemotherapy for a maximum of six cycles. Each 21-day cycle of chemotherapy consisted of the following agents administered intravenously: 1000 mg/m 2 cyclophosphamide on day 1; 50 mg/m 2 doxorubicin on day 1; and 120 mg/m 2 etoposide on days 1, 2, and 3. Filgrastim therapy was initiated on day 4, day 6, or day 8 at 5 ug/kg/day administered SC. The study drug was continued through day 18 unless the post-nadir neutrophil count exceeded 10.0 x 1O 9 /1 after day 12, in which case the study drug was discontinued for the remainder of the cycle (Figure 1 ). The cycle of treatment was planned to be repeated every 21 days for up to six cycles.
The primary endpoint of this trial was neutrophil response. To this end, complete blood counts with manual differentials were performed three times a week. Patients were required to keep a daily log of oral body temperatures.
No dose reductions were permitted on the basis of nadir blood counts alone. If adequate platelet (100 x 10 9 /l) and neutrophil (2.0 x 10 9 /l) recovery had not occurred, the next cycle of chemotherapy was delayed one week.
If patients developed fever (> 38.2 °C) and neutropenia (ANC 0.5 x 10 9 /l) during two successive cycles of treatment, subsequent chemotherapy cycles were administered at 75% of the initial doses. Treatment was delayed one week if nonhematologic toxicity was still present. Patients were to be removed from study if delays exceeded three weeks in any one cycle.
Patients who developed febrile neutropenia as defined above were treated according to the institutional guidelines with intravenous antibiotics until clinical recovery. Patients who developed thrombocytopenia with a platelet count < 20 x 1O 9 /1 and/or evidence of bleeding in the setting of lesser degrees of thrombocytopenia received platelet transfusions according to institutional guidelines.
If patients developed grade IV non-hematologic toxicity in a previous cycle of treatment, subsequent chemotherapy cycles were administered at 75% of the initial doses. Dose reductions were permanent for the remainder of the patient's treatment.
Results

Patient characteristics
Forty-six patients were randomly assigned to initiate Filgrastim therapy on day 4 (n-15), day 6 (n-16), or day 8 (n= 15). Combination (CAE) chemotherapy was administered according to the standard regimen. One patient was not included in the evaluation of treatment for safety or efficacy because he withdrew from the study before receiving chemotherapy. A summary of patient characteristics is provided in Table 1 .
Age was comparable across the three treatment groups and there was a similar distribution of men and women. Although the median Karnofsky performance status at baseline was 80% for all treatment groups, the distribution between groups varied. There was a similar incidence of previous radiation therapy. The extent of disease was also similar with a median of four sites of involvement. Baseline hematologic variables (ANC, platelet count, and hemoglobin) were comparable across the three groups.
All patients were fully evaluable for the first cycle of treatment and 30 of the 45 patients were evaluable for all six cycles of therapy. Of the 15 patients who did not complete all six cycles of treatment, five were from the day-4 treatment group, seven were from the day-6 treatment group, and three were from the day-8 group.
For the day-4 treatment group, two patients were removed from study because of disease progression, one patient for complications of febrile neutropenia (FN), one patient for prolonged neutropenia, and one patient for decreased quality of life (QOL). In the day-6 treatment group, one patient withdrew because of noncompliance, one patient died, one patient had no tumor response after two cycles of therapy, two patients had severe thrombocytopenia, one patient had prolonged neutropenia, and one patient had a decreased QOL. For the day-8 treatment group, one patient was removed for complications of FN, one patient for prolonged neutropenia, and one patient for severe thrombocytopenia. Treatment delays greater than seven days across all treatment cycles occurred in 14%, 5%, and 10% of patients on the day-4, day-6, and day-8 schedule, respectively. Three of 45 patients experienced a 25% dose reduction during the study. Each of these events occurred during cycle 3 because of previous episodes of FN. Two patients were on the day-4 schedule and one patient was on the day-6 schedule.
Neutrophil response
The population-based median ANC for each treatment group is presented in Figure 2 . The ANC is expressed on a log scale by cycle day for cycle 1 and for cycles 2 through 6. All three treatment groups experienced a similar magnitude of neutropenia; however, the time to neutropenia and recovery corresponded to day of initiation of treatment in cycle 1. In cycle 2, an improvement in neutropenia was seen in all three groups. Early increases in ANC before the neutrophil nadir are seen in the day-4 group and to a lesser extent in the day-6 group, but not in the day-8 group. Both day-4 and day-6 groups have similar patterns of neutrophil recovery. By contrast, neutrophil recovery in the day-8 group is delayed.
The patient-based median ANC nadir and duration by treatment group are shown in Figure 3 . In cycle 1, the incidence of grade IV neutropenia for day-4, day-6, and day-8 groups was 72%, 75%, and 72%, respectively. As shown, the ANC nadir was 0.05 x 10 9 /l for all three groups. The median duration of grade IV neutropenia was three days for the day-4 and day-6 groups, and two days for the day-8 group. In subsequent cycles, the median ANC nadir improved substantially for the day-4 and day-6 group to 1.0 x 10 9 /l or greater for all cycles after cycle 2. By contrast, the median ANC nadir for the day-8 group remained approximately 0.2 x 10 9 /l for cycles 2 through 6. This improvement in ANC nadir for the day-4 and day-6 groups was associated with a decreased incidence of grade IV neutropenia such that the median duration was zero for all cycles after cycle 2. The day-8 group continued to have a high incidence of grade IV neutropenia with a median duration between two and three days for all remaining cycles of treatment.
To confirm that these differences in neutrophil recovery in later cycles of treatment were not due to differences in patient dropout, a subset analysis restricted to patients completing all six cycles of therapy was performed. In this analysis the same patterns were seen with more profound grade IV neutropenia and delayed neutrophil recovery in the day-8 group compared with the day-4 and day-6 groups.
Clinical aspects of neutropenia
Across all treatment cycles, FN was experienced as follows: ten episodes in five patients for the day-4 group; seven episodes in six patients for the day-6 group; and ten episodes in six patients for the day-8 group. Although these results are similar overall, the frequency of FN by cycle differed between the groups and corresponded to the differences seen in neutrophil recovery (Table 2) .
There were 13 episodes of FN in cycle 1 for an incidence of 28.9%. Five events occurred in the day-4 group, six events in the day-6 group, and two events in the day-8 group. No dose reduction occurred in cycle 2 in these patients with FN.
Of interest, all five patients in the day 4 group who had FN in cycle 1 experienced a subsequent event. Three events occurred during cycle 2, one event during cycle 3, and one event during cycle 4. Of the six patients with FN in cycle 1 in the day-6 group, one patient experienced a second episode of FN during cycle 3. There were no episodes of FN in later cycles for patients in the day-4 and day-6 groups if they did not experience it during cycle 1.
In the day-8 group, one of the two patients who experienced FN during cycle 1 also had subsequent FN during cycles 2 and 3. In addition, and unlike the day-4 and day-6 groups, six additional episodes of FN occurred during cycles 3 through 6 in four patients who did not experience FN during cycle 1. 
Other hematologic variables
The median platelet nadir and percent of patients with grade IV thrombocytopenia by cycle and treatment group are presented in Figure 4 . The median platelet nadir was similar for all treatment groups in the first cycle and remained > 50 x 10 9 /l for all cycles of therapy for the day-4 and day-6 group. By contrast, the day-8 group had platelet nadir decreasing to approximately 20 x 10/1 in cycles 5 and 6.
For the day-8 group, the incidence of grade IV thrombocytopenia increased from < 10% in cycles 1-3 to > 50% in cycles 5 and 6. A subset analysis limited to patients completing all six cycles of treatment demonstrated similar trends in cumulative thrombocytopenia in the day-8 group.
The increased frequency of thrombocytopenia in the day-8 group corresponded to a higher frequency of platelet transfusions compared with the day-4 and day-6 groups ( Table 3) . One or two patients in each group required platelet transfusions in each of the first three cycles of treatment. In each of the last three cycles of treatment, one, or two patients in the day-4 and day-6 groups required transfusion in each cycle compared with five to seven patients in the day-8 group.
Despite the differences in ANC and platelet recovery in later cycles of treatment for the day-8 group compared with the day-4 and day-6 groups, no differences in anemia were seen. All three groups experienced a decrease in hemoglobin from a median of 12.8 g/dl before cycle 1 to 10.6 g/dl before cycle 6. Red cell transfusions were needed in eight of 14 patients in the day-4 group, 12 of 16 patients in the day-6 group, and 12 of 15 patients in the day-8 group. A median of two units were transfused, with a range of one to 12 units.
Duration of filgrastim therapy
The duration of Filgrastim treatment was a function of the day of initiation of therapy and the time to ANC recovery. The median time to ANC recovery (> 10 x 10 9 /l) was similar across all three treatment groups and all six cycles ranging from 13 to 15 days. Across all patient cycles, the median duration of Filgrastim therapy was 11 days for the day-4 group with a range of eight to 15 days. The day-6 group had a median duration of nine days with a range of seven to 13 days, and the day-8 group had a median duration of seven days with a range of six to 11 days.
Other clinical outcomes
Response and survival were similar in all three treatment groups. The overall complete and partial response rate was 73%. The median survival was 13 months. No deaths occurred because of neutropenia or other treatment-related side effects.
Adverse event reporting was similar across all three treatment groups. The most frequently reported adverse event related to Filgrastim was musculoskeletal pain, occurring in 40% of all patients.
Discussion
Unlike many other phase 2 trials evaluating the impact of cytokines post-chemotherapy, this trial has the benefit of a large database from a previous phase 3 trial. This previous trial used the same chemotherapy regimen (CAE) in the same patient population (SCLC) [4] . Patient eligibility criteria were similar in this trial except that accrual was limited to patients with extensive stage disease only, whereas the previous trial also included limited-stage patients. The current trial was different in that no dose reduction was allowed for the first episode of FN, assuring maintenance of full doses of chemotherapy through at least the first two cycles of treatment.
The previous trial was based on a clinical endpoint of FN. In that study, the close correlation between the severity and duration of neutropenia and the risk of FN was again confirmed [7] . In the present study, neutrophil variables were used as a surrogate marker for clinical risk of infection to evaluate the impact of Filgrastim schedule variation post-chemotherapy. The results suggest that varying the date of initiation of Filgrastim from one day to three days or five days post-chemotherapy, has a substantial impact on hematologic recovery and related clinical outcome.
Analysis of cycle 1 of the current study revealed a similar degree of neutropenia in all three groups (day 4, day 6 and day 8) comparable to the results observed in the phase 3 trial [4] . All three groups showed superior neutrophil recovery compared with the six days of grade IV neutropenia seen on the placebo arm of the original trial. As in the phase 3 trial, an improvement of the ANC nadir and the duration of neutropenia occurred in cycle 2 and subsequent cycles of treatment; however, this 'priming' effect was more pronounced in the day-4 and day-6 groups. The day-8 group continued to have a similar severity and duration of neutropenia through all six cycles of treatment. On this basis, it would appear that delay of Filgrastim to day 8 is associated with suboptimal neutrophil recovery.
Although the overall incidence of FN was similar in all three groups, the sample size is too small to make any definitive statements about the optimal schedule of Fil- grastim based on clinical variables. The priming effect of Filgrastim on neutrophil recovery was observed in the original randomized trial [4] . The median days of grade IV neutropenia was reduced from three days in cycle 1 to one day or less in subsequent cycles in the Filgrastim group. By contrast, grade IV neutropenia was six days in cycle 1 in the placebo group and worsened over successive cycles. This reversal of the cumulative effect of chemotherapy on myelopoiesis has been noted in other growth-factor trials and has been attributed to expansion of myeloid precursors before subsequent cycles of chemotherapy [6] . Attempts to initiate colonystimulating factors before chemotherapy have not been able to achieve this priming effect in the first cycle of chemotherapy. This may be due to extreme schedule dependency or an interaction with endogenous hematopoietic growth factors and/or cycling progenitor cells in myelosuppression.
This current study would suggest that at least a portion of this priming effect is schedule dependent. Delay of Filgrastim until day 8 postchemotherapy resulted in a loss of the priming effect seen with the day-4 and the day-6 schedules. The clinical result was continued neutropenia and episodes of FN in the day-8 group in later cycles of chemotherapy that was not seen with the day-4 or day-6 schedules. It is of interest that the day-8 group continued to have episodes of FN in later cycles of chemotherapy corresponding to the greater degree of neutropenia present in this group. By contrast, the day-4 and day-6 patients had most episodes of FN in the earlier cycles of chemotherapy.
In the day-4 and day-6 groups, all episodes of FN post-cycle 1 were in patients who had already experienced FN. Of the 11 patients with FN, six had a subsequent febrile neutropenic event. This emphasizes that patients with FN in the first cycle of chemotherapy remain at increased risk of FN during subsequent cycles of chemotherapy. It is unclear if this increased risk is due to host factors or, if it indicates a poor response to the 'priming' effect of Filgrastim. Despite continued use of Filgrastim, dose reduction of chemotherapy should be considered in these patients.
Although the 'priming' effect of Filgrastim on neutrophil recovery remains poorly understood, this study would suggest that delay of the initiation of Filgrastim may reduce this effect. It is of interest that the day-8 group also developed more profound thrombocytopenia in later cycles of treatment. Corresponding to the increased incidence of thrombocytopenia was a higher incidence of platelet transfusions in the day-8 group. This would suggest that either the day-8 schedule allowed an increased severity of thrombocytopenia or that the other schedules were, in fact, associated with a beneficial effect on platelet recovery. It is unlikely that the day-8 schedule actually increased the severity of thrombocytopenia. The incidence of grade IV thrombocytopenia in this group was similar to patients on the placebo arm of the original phase 3 trial.
Alternatively, Filgrastim may have a beneficial effect on reducing the cumulative thrombocytopenia associated with chemotherapy. While this effect was not demonstrated in the phase 3 trial, the analysis was complicated by the fact that the Filgrastim patients received a more dose-intensive regimen compared with patients remaining in the blinded placebo group of the study. Beneficial effects of Filgrastim on platelet recovery have been demonstrated in other settings, including a trial of intensive consolidation chemotherapy in acute myeloid leukemia [8] . In this study, there was a significant reduction in the duration of both neutropenia and thrombocytopenia compared with an earlier cohort that did not receive Filgrastim support.
Another possible explanation to the lack of neutrophil 'priming' and the increased severity of cumulative thrombocytopenia in the day-8 group could simply be a difference in the population of patients on this arm of the study. Careful analysis of pretreatment characteristics, however failed to reveal a difference in prognostic factors or laboratory variables. Differential drop-out of patients could also effect the results, but analysis restricted to patients who finished all six cycles of treatment in the three arms of the study revealed similar results. In addition, there were no differences in delivered dose intensity. Overall response and survival were comparable for the three groups, although the study was not powered to demonstrate differences. This trial supports the concept that Filgrastim has independent effects on cell differentiation of the postmitotic pool as well as amplification of the progenitor population [6] . While the former effect accounts for the early increase in neutrophils before the nadir, it is the latter effect of cell amplification that is critical to reducing neutropenia related to chemotherapy. This study would suggest that delayed use of Filgrastim postchemotherapy may decrease the cell amplification effect. In this chemotherapy regimen, the neutrophil recovery for both day-4 and day-6 schedules appear similar suggesting that there is a window of opportunity for the optimal effect of Filgrastim therapy. Filgrastim use was reduced from a median of 11 days for the day-4 schedule (identical to the earlier phase 3 trial) to nine days for the day-6 schedule. This reduction on duration of Filgrastim therapy without apparent reduction in efficacy has important cost implications [9] . If confirmed in other settings, these findings shift the equation that has been used to determine the costs associated with Filgrastim therapy [10] .
Randomized trials of dose intensity in small-cell carcinoma of the lung have yet to demonstrate a survival benefit. However, understanding how to optimize drug combinations and ameliorate toxicities remains crucial to improving outcomes for all patients with cancer. The CAE regimen used in this study has been useful as a model of myelosuppression to evaluate the effect of hematopoietic growth factors on reducing myelosuppression, clinical complications, and cough [9, 10] . Although further studies are clearly warranted, the results of this trial may be applicable to other dose-intensive regimens.
In the current era of cost containment and judicious use of resources, demonstrated effect on outcome becomes more important. While many oncologists have individualized their scheduling of colony stimulatingfactors in an attempt to be cost effective, this trial suggests that such changes may have unforeseen consequences. It is hoped that this trial will encourage investigators to explore other issues of dose and schedule for colony-stimulating factors in a variety of disease and chemotherapy settings. From these results, hopefully we can refine and optimize our use of these potent biological agents.
